A Phase 2 interventional study of NNZ-2591 in Angelman Syndrome, sponsored by Neuren Pharmaceuticals Limited. Completed at 3 sites in Australia. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by Neuren Pharmaceuticals Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution, 50mg/L, in children and adolescents with Angelman syndrome. The secondary purpose is to investigate measures of efficacy of subjects will receive treatment of 50mg/mL orally administered NNZ-2591 for a total of 13 weeks
52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.
This study's enrollment of 17 is below the median of 66 across 29 interventional studies indexed under Angelman Syndrome.
Browse Angelman Syndrome studies →Neuren Pharmaceuticals Limited is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Drug: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Also known as: Cyclo-L-Glycyl-L-2-Allylproline
Safety and Tolerability
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Time frame: 13 weeks
Pharmacokinetic - Typical AUC24 of 30kg Child
Area under the concentration-time curve of NNZ-2591 over 24 hours
Time frame: 13 weeks
Pharmacokinetic - Typical t1/2 in 30 kg Child
Apparent terminal elimination half-life of NNZ-2591
Time frame: 13 weeks
Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)
Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I). Score on a Likert scale (1-7) where lower scores are better
Time frame: 13 weeks
Caregiver Impression of Improvement : Overall Score
Caregiver Impression of Improvement: Overall Score. Measured on a 7-point Likert scale (1-7) where lower scores are better.
Time frame: 13 weeks
Angelman syndrome-specific Clinical Global Impression Scale - Severity (CGI-S): Overall Score
Angelman syndrome-specific Clinical Global Impression Scale-Severity (CGI-S): Change from baseline on overall score based on a 7-point Likert scale (1-7) where lower scores are better.
Time frame: 13 weeks
Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS)
Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS). Change from baseline in total score based on a 5-point Likert scale (0-4) where lower scores are better.
Time frame: 13 weeks
Caregiver Top 3 Concerns
Caregiver Top 3 Concerns: Change from baseline in Average Concerns Severity.
Time frame: 13 weeks
MacArthur-Bates Communicative Development Inventory (MB-CDI)
MacArthur-Bates Communicative Development Inventory (MB-CDI)
Time frame: 13 weeks
Observer-Reported Communication Ability (ORCA)
Observer-Reported Communication Ability (ORCA). Change from baseline in modified t-score. Scores range from 25.8 - 83.8 with higher scores indicating greater communication abililty. A positive change from baseline indicates improvement
Time frame: 13 weeks
Aberrant Behavior Checklist-2 (ABC-2)
Aberrant Behavior Checklist-2 (ABC-2) - Change from baseline in total score. Higher scores indicate more behavioral issues. A negative change from baseline indicates improvement.
Time frame: 13 weeks
Child Sleep Habits Questionnaire (CSHQ)
Child Sleep Habits Questionnaire (CSHQ). Change from baseline in total score. Range of scores was (33-99) with higher scores being worse
Time frame: 13 weeks
Gastrointestinal Health Questionnaire (GIHQ)
Gastrointestinal Health Questionnaire (GIHQ)
Time frame: 13 weeks
Vineland Adaptive Behavior Scales-3, Interview version
Vineland Adaptive Behavior Scales-3, Interview version; Composite standard score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Bayley Scales of Infant Development-4, Vineland Motor subscales
Time frame: 13 weeks
Quality of Life Inventory-Disability (QI-Disability)
Quality of Life Inventory-Disability (QI-Disability). Change from baseline inoverall score. Scores range from 0-100 with higher scores indicating better quality of life. A positive change indicates improvement
Time frame: 13 weeks
Impact of Childhood Neurological Disability (ICND)
Impact of Childhood Neurological Disability (ICND): Change from baseline in overall quality of life rating. Scores range from 1-6, with a higher score indicating better quality of life. A positive change from baseline indicates improvement
Time frame: 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in May 2024, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ercanetide
Neuren Pharmaceuticals Limited